FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved standalone treatment for this condition.
HealthDay on MSN22h
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionThe U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback